

Laurus Labs Limited
Corporate Office
2nd Floor, Serene Chambers, Road No. 7
Banjara Hills, Hyderabad - 500034, Telangana, India
T +91 40 39804333 / 2342 0500 / 501
F +91 40 3980 4320



To The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25 th Floor, Dalal Street Mumbai – 400001 Code: 540222	To The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051 Code: LAURUSLABS
--	---

Dear Sirs,

Sub: Laurus Labs and Aspen Pharmacare launch an improved triple combination HIV drug in South Africa

Laurus Labs Ltd (“the Company”) is pleased to announce that the Company and Aspen Pharmacare, South Africa have launched a new HIV drug with the triple combination of Tenofovir Disoproxil Fumarate, Lamivudine and Dolutegravir (TLD) in South Africa on 26 November 2018.

A press release to this extent is also attached for your information and records.

Thanking you,

Yours sincerely,
For Laurus Labs Limited

G. Venkateswar Reddy
Company Secretary



Encl: a.a.

Laurus Labs and Aspen Pharmacare launch an improved triple combination HIV drug in South Africa

Hyderabad, December 02, 2018, Laurus Labs Ltd. (Laurus BSE: 540222, NSE: Lauruslabs, ISIN: INE947Q01010)

Laurus Labs, a leading integrated pharmaceutical company in India with presence across the globe and partner, Aspen Pharmacare, South Africa's leading pharmaceutical company, have launched a new HIV drug with the triple combination of Tenofovir Disoproxil Fumarate, Lamivudine and Dolutegravir (TLD) in South Africa on 26 November 2018.

Earlier, Aspen Pharma received approvals for the dossier where Aspen Port Elizabeth and Laurus Labs Visakhapatnam are registered as manufacturing facilities, from the South African Health Products Regulatory Authority (SAHPRA). Named Emdolten™, the product provides significant benefits to existing therapies, including countering drug resistance that often develops with older HIV treatments. This once-a-day triple combination tablet is positioned to become a preferred first-line ARV choice in multiple markets. It will be available in 50mg/300mg/300mg dosages.

As part of the partnership, Aspen launched the product in South Africa for the private market and Laurus Labs will supply the API, from its manufacturing facility located in Jawaharlal Nehru Pharma city, Visakhapatnam, India. This state-of-the-art facility is approved by USFDA.

Dr. Satyanarayana Chava, Founder and CEO, Laurus Labs said, "we convey our best wishes to our partner Aspen Pharma on the new product launch and we are happy to contribute to the treatment of millions of HIV patients across the globe through our fully integrated and the state of the art manufacturing facilities. I am sure that the new triple combination drug will contribute to the successful treatment of patients affected by HIV and AIDS."

Stavros Nicolaou, Senior Executive for Aspen Pharmacare stated "The Aspen Pharmacare and Laurus Labs intervention is one with an outstanding track record that has delivered millions of patient treatment packs to HIV infected patients on the African continent, Laurus Labs supplying the API and Aspen the ARV formulation. Through Emdolten™, which provides the latest ARV triple cocktail, cutting edge technology, many hundreds and thousands of patients will continue to benefit from the Aspen/Laurus intervention."

About Laurus Labs Limited

Laurus Labs is a leading research & development driven and fully integrated pharmaceutical company in India. The Company has grown consistently to become one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. Laurus also manufactures APIs in Oncology and other therapeutic areas. Its strategic and early investments in R&D and manufacturing infrastructure have enabled it to become one of the leading suppliers of APIs in the ARV therapeutic area. The company has also ventured into develop a Finished Dosages Forms on the back of existing strengths in APIs with a current capacity of 5 billion units per year, expandable up to 8 billion units per year. The Company is also driving growth opportunities in the Synthesis and Ingredients businesses. Corporate Identification No: L24239AP2005PLC047518.

For more information about us, please visit <http://www.lauruslabs.com> or Contact particulars:

Pavan Kumar N
Laurus Labs Ltd.

Tel:
+914039834380/+919246564666/7337353848

Email: mediarelations@lauruslabs.com

DISCLAIMER: Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Laurus Labs Limited (Laurus) will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

